These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 22791984)

  • 21. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing.
    Mercadante S
    Crit Rev Oncol Hematol; 2011 Dec; 80(3):460-5. PubMed ID: 21215653
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Budget impact analysis of the fentanyl buccal tablet for treatment of breakthrough cancer pain.
    Darbà J; Kaskens L; Sánchez-de la Rosa R
    Clinicoecon Outcomes Res; 2013; 6():1-9. PubMed ID: 24368889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacotherapy for breakthrough cancer pain.
    Mercadante S
    Drugs; 2012 Jan; 72(2):181-90. PubMed ID: 22233484
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.
    Mercadante S; Prestia G; Adile C; Casuccio A
    J Pain; 2014 Jun; 15(6):602-7. PubMed ID: 24561001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How practical are transmucosal fentanyl products for breakthrough cancer pain? Novel use of placebo formulations to survey user opinion.
    England R; Maddocks M; Manderson C; Zadora-Chrzastowska S; Wilcock A
    BMJ Support Palliat Care; 2011 Dec; 1(3):349-51. PubMed ID: 24653483
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fentanyl for breakthrough pain: a systematic review.
    Davis MP
    Expert Rev Neurother; 2011 Aug; 11(8):1197-216. PubMed ID: 21797660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review of rapid-onset opioids for breakthrough pain in patients with cancer.
    Simon SM; Schwartzberg LS
    J Opioid Manag; 2014; 10(3):207-15. PubMed ID: 24944071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New formulations of fentanyl for acute pain management.
    Paech MJ; Bloor M; Schug SA
    Drugs Today (Barc); 2012 Feb; 48(2):119-32. PubMed ID: 22384452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain.
    Shimoyama N; Gomyo I; Teramoto O; Kojima K; Higuchi H; Yukitoshi N; Ohta E; Shimoyama M
    Jpn J Clin Oncol; 2015 Feb; 45(2):189-96. PubMed ID: 25378647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Healthcare professionals' views of the use of oral morphine and transmucosal diamorphine in the management of paediatric breakthrough pain and the feasibility of a randomised controlled trial: A focus group study (DIPPER).
    Jamieson L; Harrop E; Johnson M; Liossi C; Mott C; Oulton K; Skene SS; Wong IC; Howard RF
    Palliat Med; 2021 Jun; 35(6):1118-1125. PubMed ID: 33845654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Oral transmucosal fentanyl citrate (OTFC) in the treatment of breakthrough pain].
    Borgbjerg FM; Rosenberg J
    Ugeskr Laeger; 2000 Sep; 162(39):5237-40. PubMed ID: 11043058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials.
    Jandhyala R; Fullarton JR; Bennett MI
    J Pain Symptom Manage; 2013 Oct; 46(4):573-80. PubMed ID: 23380337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A New Therapeutic Approach for Cancer-Related Breakthrough Pain - Focused on Oral Transmucosal Fentanyl].
    Yomiya K; Kaneshima M; Kyosaka B; Warita E; Hosonuma R; Osato S
    Gan To Kagaku Ryoho; 2017 Apr; 44(4):289-293. PubMed ID: 28428506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics.
    Mystakidou K; Katsouda E; Parpa E; Tsiatas ML; Vlahos L
    Am J Hosp Palliat Care; 2005; 22(3):228-32. PubMed ID: 15909786
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics.
    Mystakidou K; Katsouda E; Parpa E; Tsiatas ML; Vlahos L
    J Opioid Manag; 2005; 1(1):36-40. PubMed ID: 17315410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Considerations in selecting rapid-onset opioids for the management of breakthrough pain.
    Smith HS
    J Pain Res; 2013; 6():189-200. PubMed ID: 23503653
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Opioids for the management of breakthrough cancer pain in adults: a systematic review undertaken as part of an EPCRC opioid guidelines project.
    Zeppetella G
    Palliat Med; 2011 Jul; 25(5):516-24. PubMed ID: 21708858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of non-intravenous formulations of fentanyl.
    Lötsch J; Walter C; Parnham MJ; Oertel BG; Geisslinger G
    Clin Pharmacokinet; 2013 Jan; 52(1):23-36. PubMed ID: 23100195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM; Messina J; Xie F; Hale M
    Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comprehensive review of rapid-onset opioids for breakthrough pain.
    Smith H
    CNS Drugs; 2012 Jun; 26(6):509-35. PubMed ID: 22668247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.